Alkem Laboratories

Alkem Laboratories EBIT Margin

The EBIT Margin (Operating Margin) of Alkem Laboratories (ALKEM.NS) as of Oct 21, 2026 is 20.61 %. In the previous year, EBIT Margin (Operating Margin) was 20.42 % — a change of 0.93% (higher).

EBIT Margin

20.61 %

YoY

0.93%

Last updated:

EBIT Margin (Operating Margin) of Alkem Laboratories is 2026 20.61 % . EBIT Margin (Operating Margin) of Alkem Laboratories was 2025 20.42 % . It decreases by 0.93% higher compared to the previous year.

For Alkem Laboratories, the operating (EBIT) margin of 20.6% is up versus 17.9% a few years ago.

The Alkem Laboratories EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
13.82 INR
Jan 1, 2020
15.54 INR
Jan 1, 2021
21.66 INR
Jan 1, 2022
17.93 INR
Jan 1, 2023
11.66 INR
Jan 1, 2024
17.03 INR
Jan 1, 2025
20.42 INR
Jan 1, 2026
20.61 INR
The Alkem Laboratories EBIT Margin history
YEAREBIT MarginYoY
20.61 %+0.93%
20.42 %+19.86%
17.03 %+46.06%
11.66 %-34.97%
17.93 %-17.22%
21.66 %+39.41%
15.54 %+12.41%
13.82 %-2.54%
14.18 %-12.55%
16.22 %+2.18%
15.87 %+57.33%
10.09 %-23.89%
13.26 %+6,944.45%
0.19 %-4.71%
0.20 %+15.24%
0.17 %+17.52%
0.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alkem Laboratories stock

EBIT Margin (Operating Margin) of Alkem Laboratories is 20.61 % in 2026.

EBIT Margin (Operating Margin) of Alkem Laboratories changed from 20.42 % to 20.61 %, representing a 0.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Alkem Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Alkem Laboratories

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Alkem Laboratories